Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention

被引:106
作者
DeFronzo, Ralph A. [1 ]
Abdul-Ghani, Muhammad [1 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Diabet Div, San Antonio, TX 78229 USA
关键词
IMPAIRED GLUCOSE-TOLERANCE; BETA-CELL FUNCTION; LIFE-STYLE INTERVENTION; CLAUDE-BERNARD-LECTURE; INSULIN-RESISTANCE; FASTING GLUCOSE; PLASMA-GLUCOSE; FOLLOW-UP; HIGH-RISK; METFORMIN;
D O I
10.2337/dc11-s221
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the U.S., similar to 21 X 10(6) individuals have type 2 diabetes, and twice as many have impaired glucose tolerance (IGT). Approximately 40-50% of individuals with IGT will progress to type 2 diabetes over their lifetime. Therefore, treatment of high-risk individuals with IGT to prevent type 2 diabetes has important medical, economic, social, and human implications. Weight loss, although effective in reducing the conversion of IGT to type 2 diabetes, is difficult to achieve and maintain. Moreover, 40-50% of IGT subjects progress to type 2 diabetes despite successful weight reduction. In contrast, pharmacological treatment of IGT with oral antidiabetic agents that improve insulin sensitivity and preserve beta-cell function-the characteristic pathophysiological abnormalities present in IGT and type 2 diabetes-uniformly have been shown to prevent progression of IGT to type 2 diabetes. The most consistent results have been observed with the thiazolidinediones (Troglitazone in the Prevention of Diabetes [TRIPOD], Pioglitazone in the Prevention of Diabetes [PIPOD], Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication [DREAM], and Actos Now for the Prevention of Diabetes [ACT NOW]), with a 50-70% reduction in IGT conversion to diabetes. Metformin in the U.S. Diabetes Prevention Program (DPP) reduced the development of type 2 diabetes by 31% and has been recommended by the American Diabetes Association (ADA) for treating high-risk individuals with IGT. The glucagon-like peptide-1 analogs, which augment insulin secretion, preserve beta-cell function, and promote weight loss, also would be expected to be efficacious in preventing the progression of IGT to type 2 diabetes. Because individuals in the upper tertile of IGT are maximally/near-maximally insulin resistant, have lost 70-80% of their beta-cell function, and have an similar to 10% incidence of diabetic retinopathy, pharmacological intervention, in combination with diet plus exercise, should be instituted.
引用
收藏
页码:S202 / S209
页数:8
相关论文
共 60 条
[21]   From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus [J].
DeFronzo, Ralph A. .
DIABETES, 2009, 58 (04) :773-795
[22]  
Diabetes Prevention Progam, 2005, DIABETES, V54, P1150
[23]   Predictors of progression from impaired glucose tolerance to NIDDM - An analysis of six prospective studies [J].
Edelstein, SL ;
Knowler, WC ;
Bain, RP ;
Andres, R ;
BarrettConnor, EL ;
Dowse, GK ;
Haffner, SM ;
Pettitt, DJ ;
Sorkin, JD ;
Muller, DC ;
Collins, VR ;
Hamman, RF .
DIABETES, 1997, 46 (04) :701-710
[24]   PREVENTION OF TYPE-2 (NON-INSULIN-DEPENDENT) DIABETES-MELLITUS BY DIET AND PHYSICAL EXERCISE - THE 6-YEAR MALMO FEASIBILITY STUDY [J].
ERIKSSON, KF ;
LINDGARDE, F .
DIABETOLOGIA, 1991, 34 (12) :891-898
[25]  
Espeland M, 2007, DIABETES CARE, V30, P1374
[26]   β-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes:: A new analysis [J].
Ferrannini, E ;
Gastaldelli, A ;
Miyazaki, Y ;
Matsuda, M ;
Mari, A ;
DeFronzo, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (01) :493-500
[27]   Thiazolidinediones improve β-cell function in type 2 diabetic patients [J].
Gastaldelli, Amalia ;
Ferrannini, Ele ;
Miyazaki, Yoshinori ;
Matsuda, Masafumi ;
Mari, Andrea ;
DeFronzo, Ralph A. .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2007, 292 (03) :E871-E883
[28]   Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial [J].
Gerstein, H. C. ;
Yusuf, S. ;
Holman, R. R. ;
Bosch, J. ;
Anand, S. ;
Avezum, A. ;
Budaj, A. ;
Chiasson, J. ;
Conget, I. ;
Dagenais, G. ;
Davis, M. ;
Diaz, R. ;
Dinccag, N. ;
Enjalbert, M. ;
Escalante, A. ;
Fodor, G. ;
Hanefeld, M. ;
Hedner, T. ;
Jolly, K. ;
Keltai, M. ;
Laakso, M. ;
Lanas, F. ;
Lonn, E. ;
McQueen, M. ;
Mohan, V. ;
Phillips, A. ;
Piegas, L. ;
Pirags, V. ;
Probstfield, J. ;
Shaw, J. ;
Schmid, I. ;
Teo, K. ;
Zimmet, P. ;
Zinman, B. ;
Gerstein, H. C. ;
Yusuf, S. ;
Bosch, J. ;
Pogue, J. ;
Sheridan, P. ;
Dinccag, N. ;
Hanefeld, M. ;
Hoogwerf, B. ;
Laakso, M. ;
Mohan, V. ;
Shaw, J. ;
Zinman, B. ;
Holman, R. R. ;
Diaz, R. ;
Ahuad Guerrero, R. ;
Albisu, J. .
LANCET, 2006, 368 (9541) :1096-1105
[29]   Quality of diabetes care in US academic medical centers - Low rates of medical regimen change [J].
Grant, RW ;
Buse, JB ;
Meigs, JB .
DIABETES CARE, 2005, 28 (02) :337-342
[30]   THE METABOLIC PROFILE OF NIDDM IS FULLY ESTABLISHED IN GLUCOSE-TOLERANT OFFSPRING OF 2 MEXICAN-AMERICAN NIDDM PARENTS [J].
GULLI, G ;
FERRANNINI, E ;
STERN, M ;
HAFFNER, S ;
DEFRONZO, RA .
DIABETES, 1992, 41 (12) :1575-1586